about
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugsHomology modeling of dopamine D2 and D3 receptors: molecular dynamics refinement and docking evaluationInfluence of salt loading on the cardiac and renal preproendothelin-1 mRNA expression in stroke-prone spontaneously hypertensive ratsPronounced hypoperfusion during spreading depression in mouse cortex.Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanismsHomocysteine serum levels in diabetic patients with non proliferative, proliferative and without retinopathy.Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical TrialDopamine D3 receptor is necessary for ethanol consumption: an approach with buspironeHealth policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy.Vessel-specific role of sphingosine kinase 1 in the vasoconstriction of isolated basilar arteries.Decreased vascular lesion formation in mice with inducible endothelial-specific expression of protein kinase AktRole of magnesium, coenzyme Q10, riboflavin, and vitamin B12 in migraine prophylaxis.Pleiotropic effects of glitazones: a double edge sword?Ambiguities in dietary antioxidant supplementation compared to calcium channel blockers therapy.Analytical and experimental pharmacology, challenges aheadEffect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic miceFolate status in type 2 diabetic patients with and without retinopathy.Linking Notch signaling to ischemic strokeFortified extract of red berry, Ginkgo biloba, and white willow bark in experimental early diabetic retinopathy.Lipoprotein(a) serum levels in diabetic patients with retinopathy.Regulation of endothelial nitric oxide synthase and postnatal angiogenesis by Rac1.Safety profile assessment of buflomedil: an overview of adverse reactions between 1975 and 2011.Pharmacological management of ocular hypertension: current approaches and future prospective.Isoflavones: estrogenic activity, biological effect and bioavailability.Dopamine D(3) receptor as a new pharmacological target for the treatment of depression.MicroRNA target prediction in glaucoma.Role of phospholipases A2 in diabetic retinopathy: in vitro and in vivo studies.HIV-1, HIV-2, HTLV-I/II and STD among female prostitutes in Buenos Aires, Argentina.Epigenetic drugs for Alzheimer's disease: hopes and challenges.Metal fume fever.Effects of phenformin on the proliferation of human tumor cell lines.Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.Calcium antagonists and endothelial function: focus on nitric oxide and endothelin.Effects of novel hybrids of caffeic acid phenethyl ester and NSAIDs on experimental ocular inflammation.Evidence for a direct interaction of thapsigargin with voltage-dependent Ca2+ channel.Ocular drug delivery: a clue from nanotechnology.Potential drug mechanism(s) targeting the contractile status of hepatic stellate cells.Regulation of vascular tone in rabbit ophthalmic artery: cross talk of endogenous and exogenous gas mediators.Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit.Inhibition of cerebral vasoconstriction by dantrolene and nimodipine.
P50
Q26866006-52B593FC-B5E4-45FE-B163-ED3AF86164C8Q28483632-1660234B-6451-4448-B69A-E8DD2DB2B524Q28565934-A8A44666-D7CB-43E4-A443-423A7898D0F0Q33208731-05C9DEEC-FA5A-47E1-807C-051267D3201FQ33260026-03F15ECB-F215-4E63-BBDF-807C041D37C7Q33616748-D5D695A5-AF39-4A35-ADB2-E22866353872Q33647262-320B5AA3-CB33-4E71-A43B-D1A32B2D2959Q33764334-3D857B76-3161-45C3-9EFF-088A10FACDFFQ33800146-472B68FA-BF0E-45EE-BAD2-941CFD8D49FEQ34283351-7313699E-DF66-41C4-A339-13AE35AEFC19Q34331352-073B2554-0B6E-4FA5-8B45-1ED99921D9ADQ34548633-2D54D827-0C5A-45C1-B490-062B375F5495Q35025858-836108AA-A8C9-4122-B419-2A945E764FDFQ35042122-E2A80460-B5B3-40F6-8201-AB54BE9FCA7FQ35071048-038345FA-C638-457B-A72B-BF2C2437388BQ35153847-17F0EAF2-F7E8-4CF3-ABCC-6B3558813D27Q35954630-0D77024B-C682-4C9A-8737-3F3523C7E0E5Q36534456-EF2CE65F-AEBD-455E-8F07-6836392CCA12Q36914007-3932736C-EA3A-469C-A04D-53384C1DD247Q36943438-9C261746-16F9-4426-8EF1-C1B1A5F7F897Q37041713-2F66ED36-96A0-41C6-B1C8-F6A4A9222A49Q38031438-98600A24-455F-4A8E-963E-EF1CE8229440Q38052295-F8C2FE9D-FC87-4B01-BF50-56AB640389D0Q38060653-7E6322AC-2D6F-4739-A045-A00161EA3FF8Q38122970-34899B3E-BEC5-451F-946C-810ABCCBA290Q38615521-C2D589B8-1829-4F9F-9F7E-8FDD59EB154CQ39090267-693307D9-A498-4A9B-BCBE-00950D79B4A0Q39430507-505A980E-BEEB-4AB9-B8A8-389957207C16Q39456708-A6F94644-E99F-438C-8EFF-EA6FB4E45047Q40242852-78A059E8-D01B-4942-88CF-ED3A15ADDDC8Q40616042-8CE3347C-9E6F-4B30-9F54-D04D9911DA5FQ40856400-1E50566E-BBDD-4F95-9B84-A7D5681CD96DQ41220908-EAD96DCC-47FA-4207-946D-AA60A8DACEBEQ41371329-2654C826-424F-40B3-A15D-71BFC2ED3997Q41396826-865ACB63-AA67-4346-B4D7-4D6595A0548FQ41568973-5053C2CF-8F15-4A52-BBA5-D4915508996CQ41569005-BD283402-E203-47A9-8A94-D611C28B42AAQ41753137-D67550A0-AC25-4ED3-B227-6BA7AFD1BC32Q41757356-6AE3C588-F49C-465E-AE56-41C8A42BEF9DQ41904750-ED2D37A0-F2A6-41CE-8001-1FB4577F3119
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Salvatore Salomone
@ast
Salvatore Salomone
@en
Salvatore Salomone
@es
Salvatore Salomone
@nl
Salvatore Salomone
@sl
type
label
Salvatore Salomone
@ast
Salvatore Salomone
@en
Salvatore Salomone
@es
Salvatore Salomone
@nl
Salvatore Salomone
@sl
prefLabel
Salvatore Salomone
@ast
Salvatore Salomone
@en
Salvatore Salomone
@es
Salvatore Salomone
@nl
Salvatore Salomone
@sl
P106
P1153
7004070847
P21
P2798
P31
P496
0000-0001-5307-6103